Target Name: IL18BP
NCBI ID: G10068
Review Report on IL18BP Target / Biomarker Content of Review Report on IL18BP Target / Biomarker
IL18BP
Other Name(s): interleukin 18 binding protein | OTTHUMP00000196341 | Interleukin-18-binding protein | Tadekinig-alfa | tadekinig-alfa | Interleukin 18 binding protein, transcript variant H | Interleukin-18-binding protein (isoform c) | IL18BP variant C | Interleukin 18 binding protein (IL18-BP) | FVH | Interleukin 18 binding protein, transcript variant A | OTTHUMP00000179143 | Interleukin-18-binding protein (isoform b) | IL-18BP | MC51L-53L-54L homolog gene product | IL-18BPb | I18BP_HUMAN | Interleukin 18 binding protein, transcript variant C | IL18BP variant H | Interleukin-18-binding protein (isoform a) | IL18BP variant A | IL18BPa | ILA8BPA

IL-18BP: A Potential Drug Target and Biomarker

The immune system is a crucial part of our bodies, and it plays a vital role in protecting us from infection and disease. During times of inflammation, the immune system sends out a response to help eliminate the offending agent. One of the proteins involved in this response is Interleukin-18 (IL-18), which is a key mediator in the regulation of inflammation and immune responses. In recent years, researchers have become increasingly interested in identifying potential drug targets and biomarkers for IL-18, with the aim of developing new treatments for various diseases. In this article, we will explore IL-18BP, a potential drug target and biomarker for IL-18, and its potential in the treatment of inflammation and immune-related diseases.

IL-18BP: The Potential Drug Target

IL-18 is a cytokine that is produced by various cell types in response to an infection or injury. It plays a crucial role in the regulation of inflammation and immune responses by promoting the recruitment of immune cells to the site of injury or infection. One of the key activities of IL-18 is its ability to stimulate the production of pro-inflammatory cytokines, such as TNF-伪, IL-6, and IL-8. These cytokines help to recruit additional immune cells to the site of injury or infection, where they can help to eliminate the offending agent.

Research has shown that IL-18 can be a potential drug target for various diseases, including cancer, autoimmune disorders, and inflammatory diseases. One of the main reasons for this interest is the ability of IL-18 to promote the development of cancer cell populations. For example, studies have shown that IL-18 can promote the migration of cancer cells to new sites of growth and can also stimulate the production of immune cells that are supportive of cancer growth.

In addition to its role in cancer growth, IL-18 has also been shown to play a key role in the development of autoimmune disorders. These disorders result from the immune system becoming too aggressive and attacking the body's own tissues. IL-18 has been shown to contribute to this process by promoting the production of pro-inflammatory cytokines that can help to recruit additional immune cells to the site of injury or damage.

IL-18BP: A Biomarker for IL-18

The ability of IL-18 to promote the production of pro-inflammatory cytokines makes it an attractive target for drug development. One of the challenges in identifying potential drug targets for IL-18 is the lack of specific and reliable biomarkers that can be used to measure the activity of these targets. In recent years, researchers have developed a new biomarker, called IL-18BP, that may be able to serve as a potential indicator of the activity of IL-18 targets.

IL-18BP is a 14-kDa protein that is produced by various cell types in response to IL-18. It is highly expressed in the liver, and it has been shown to play a role in the regulation of inflammation and immune responses. In addition to its role in immune responses, IL-18BP has also been shown to contribute to the development of certain diseases, including cancer and autoimmune disorders.

One of the key properties of IL-18BP is its ability to interact with several different proteins, including the transcription factor NF-kappa-B. This interaction allows IL-18BP to regulate the activity of NF-kappa-B, which is a key regulator of pro-inflammatory cytokine production. By modulating the activity of NF-kappa-B, IL-18BP has been shown to contribute to the regulation of inflammation and immune responses.

In addition to its role in inflammation and immune responses, IL-18BP has also been shown to play a key role in the development of certain diseases. For example, studies have shown that IL-18BP can contribute to the development of cancer by promoting the production of pro-inflammatory cytokines and by helping to recruit additional immune cells to the site of injury or damage.

IL-18BP as a Potential Biomarker

The lack of specific and reliable biomarkers for IL-18 has made it difficult for researchers to fully understand the role of this protein in the regulation of inflammation and immune responses. IL-18BP, as a new biomarker, may be able to help to address this by providing a more specific and reliable indicator of the activity of IL-18 targets.

One of the key advantages of IL-18BP is its ability to be easily measured and correlated with the activity of IL-18 targets. For example, the activity of IL-18BP can be measured by the production of pro-inflammatory cytokines, such as TNF-伪, IL-6, and IL-8. This can be used to assess the activity of IL-18 targets and to determine if IL-18BP is able to modulate the production of these cytokines.

In addition to its ability to be easily measured, IL-18BP may also be a good biomarker for identifying potential drug targets for IL-18. By identifying the proteins that are interacting with IL-18BP and by studying the effects of these interactions on IL-18BP activity, researchers may be able to identify new targets for drug development.

IL-18BP as a Potential Drug Target

The potential of IL-18BP as a drug target is further demonstrated by its ability to modulate the activity of TNF-伪, a key mediator of inflammation and immune responses. Studies have shown that IL-18BP can inhibit the activity of TNF-伪 by binding to its receptor, leading to a decrease in the production of pro-inflammatory cytokines. This demonstrates the potential of IL-18BP as a drug target for the treatment of inflammatory and immune-related diseases.

In addition to its ability to modulate the activity of TNF-伪, IL-18BP may also be a good target for the treatment of certain cancers. Studies have shown that IL-18BP can contribute to the development of cancer by promoting the production of pro-inflammatory cytokines and by helping to recruit additional immune cells to the site of injury or damage. This suggests that IL-18BP may be a potential drug target for the treatment of certain cancers.

Conclusion

IL-18BP is a protein that is produced by various cell types in response to IL-18 and has been shown to play a role in the regulation of inflammation and immune responses. As a potential drug target and biomarker, IL-18BP has the potential to contribute to the development of new treatments for various diseases. Further research is needed to fully understand the role of IL-18BP in the regulation of inflammation and immune responses and to determine its potential as a drug target.

Protein Name: Interleukin 18 Binding Protein

Functions: Isoform A binds to IL-18 and inhibits its activity. Functions as an inhibitor of the early TH1 cytokine response

The "IL18BP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL18BP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA